SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

TSHA-102

TSHA·Taysha Gene Therapies, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Pivotal (registrational)
Time to market
If the 1H 2027 pivotal data and FDA feedback are positive, a BLA submission could follow in 2027-2028, with potential approval in 2028-2029. This timeline depends on the regulatory pathway the FDA outlines.
Why 8/10
The next hard, dated catalyst is the topline 6-month interim analysis from the REVEAL pivotal trial and FDA feedback on the BLA submission pathway, expected in the first half of 2027 (roughly 2-7 months from today). TSHA-102 is the company's sole clinical-stage asset, making this a make-or-break binary for a single-asset biotech, warranting an impact score of 8.
Actionable Insight BULLISH

The next major binary catalyst is the topline 6-month interim analysis from the REVEAL pivotal trial and FDA feedback on the BLA submission pathway, both expected in the first half of 2027. Positive data and regulatory alignment could open a clear path to approval and drive significant upside; negative data or FDA pushback would be a severe setback for this single-asset company.

Price Chart

Loading chart...

Executive Summary

TSHA-102 is Taysha Gene Therapies' lead and only clinical-stage asset: a one-time intrathecal AAV9 gene therapy for Rett syndrome, a rare genetic neurological disorder. The drug has shown broad, durable functional improvements with a favorable safety profile in Phase 1/2 REVEAL Part A data, and has received FDA Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Dosing in the 17-patient REVEAL pivotal trial completed in mid-2026. The next major catalyst is the topline 6-month interim analysis and FDA feedback on the BLA submission pathway, expected in the first half of 2027. Taysha is a single-asset biotech with roughly $455M in cash (runway into H2 2028) and a strongly bullish analyst consensus (mean target $13 vs ~$4.11 current). Competition from Neurogene's NGN-401 is a key risk.

How It Works

TSHA-102 is a one-time gene therapy for Rett syndrome, a rare genetic neurological disorder caused by mutations in the MECP2 gene. It uses a harmless AAV9 virus shell to deliver a working copy of the MECP2 gene directly into the central nervous system via a lumbar spinal injection. The therapy includes a built-in 'miRARE' regulatory element designed to prevent the therapy from producing too much MeCP2 protein, which could be toxic. The goal is to address the root genetic cause of Rett syndrome with a single treatment.

Trial Status

Dosing completed in the REVEAL pivotal trial (N=17 patients, ages 6+) and the ASPIRE trial (N=4, ages 2-5). Longer-term data from REVEAL Part A (Phase 1/2) showed broad, multi-domain functional impact that deepened over time through 12+ months post-treatment. The drug was generally well-tolerated with no treatment-related serious adverse events or dose-limiting toxicities. Topline data from the 6-month interim analysis of the pivotal trial is expected in 1H 2027.

The Two-Sided Case

▲ Bull Case6
TSHA-102 has shown broad, multi-domain functional improvement that deepened over time through 12+ months in REVEAL Part A, regardless of age or disease severity.
The drug has been generally well-tolerated with no treatment-related serious adverse events or dose-limiting toxicities across the REVEAL Phase 1/2 and pivotal trials.
Multiple FDA regulatory designations (Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease) signal agency interest and could accelerate the BLA pathway.
Analyst consensus is strongly bullish: 18 analysts with 7 strong buy, 11 buy, 1 hold; mean price target of $13 implies roughly 209% upside from the current ~$4.11 price.
Cash runway extends into H2 2028 (reportedly ~$455.4M), funding the company through pivotal data collection and potential BLA submission.
Taysha regained full global rights to TSHA-102 in October 2025, keeping 100% of any future commercial value.
▼ Bear Case5
Single-asset risk: TSHA-102 is Taysha's only clinical-stage program; any clinical setback would devastate the stock.
Competition from Neurogene's NGN-401, which also has FDA Breakthrough Therapy designation and is in a registrational trial (EMBOLDEN) with topline data expected in 2H 2027, could split the Rett syndrome gene therapy market.
Elevated short-sale volume: the 20-session short-sale ratio of 63.75% is above the ticker's own baseline of 54.85% (z-score 1.58), indicating elevated bearish positioning.
Several tracked institutional holders trimmed or exited in Q3 2026, including Barclays (-74.7%), Citigroup (-61.6%), and Jane Street (-89.8%).
Pre-revenue with a Q3 2026 net loss of $39.13 million; the company burns cash while awaiting pivotal data.

Upcoming Catalysts

  • Topline 6-month interim analysis from the REVEAL pivotal trial (expected 1H 2027)
  • FDA feedback on BLA submission pathway (expected 1H 2027)
  • Potential BLA filing (timeline dependent on FDA feedback)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Taysha Gene Therapies, Inc. PRESS-RELEASE TSHA ·Originating report

Sources · 10

Hover a chip for the title
1 markets.businessinsider.com2 theglobeandmail.com3 seekingalpha.com4 streetinsider.com5 streetinsider.com6 nasdaq.com7 businesswire.com8 news.alphastreet.com9 marketscreener.com10 morningstar.com